RadNet, Inc. (NASDAQ: RDNT) generates a steady flow of news as a national provider of freestanding, fixed-site diagnostic imaging services and as the parent of DeepHealth, its AI-powered health informatics division. News about RadNet often highlights developments across its network of 407 owned and/or operated outpatient imaging centers in markets such as Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas, as well as updates from its Digital Health segment.
Investors and observers following RDNT news will encounter announcements on topics such as acquisitions of imaging centers, expansion into new regional markets and updates on RadNet’s operational performance. For example, the company has reported acquisitions like Radiology Regional in Southwest Florida, adding multiple imaging centers and staff to its Florida footprint. Earnings releases and financial guidance updates are also frequent news items, reflecting trends in imaging volumes, segment revenue and Adjusted EBITDA for both the Imaging Center and Digital Health segments.
RadNet’s DeepHealth division is another major source of news, with press releases covering the launch of AI-powered clinical suites, imaging informatics platforms and collaborations with partners. Recent communications have described products such as Breast Suite, Thyroid Suite, Operations Suite, Diagnostic Suite and TechLive, as well as research findings published in scientific journals and showcased at industry conferences like RSNA. News may also cover strategic collaborations, including letters of intent and partnerships with companies such as GE HealthCare to expand AI-powered imaging solutions across modalities and geographies.
Because RadNet regularly issues updates on its financial results, acquisitions, digital health initiatives and research milestones, the RDNT news page can be a useful resource for tracking how the company’s imaging center operations and DeepHealth portfolio evolve over time. Readers interested in diagnostic imaging services, AI in radiology and healthcare operations technology may find RadNet’s news particularly relevant.
RadNet (NASDAQ: RDNT) reported record first quarter 2026 results, with revenue up 22.1% to $575.6 million and Adjusted EBITDA(1) up 36.3% to $63.3 million. Digital Health revenue grew 51.5% to $29.1 million and ARR(4) rose to $96.9 million.
Advanced imaging volumes increased 19.7% systemwide. Adjusted diluted loss per share(3) improved to $(0.28). RadNet raised 2026 Imaging Center guidance for revenue to $2.355–$2.405 billion, Adjusted EBITDA(1) to $340–$353 million, and Free Cash Flow(2) to $112–$122 million, and reaffirmed all Digital Health guidance ranges.
RadNet (NASDAQ: RDNT) formed a joint venture with Saint Alphonsus Health System by acquiring a majority equity stake in Intermountain Medical Imaging, owner of five outpatient multimodality imaging centers in Boise, Idaho.
RadNet will manage operations, Gem State Radiology will continue professional services with ~30 radiologists, and the centers will deploy DeepHealth clinical, reporting, AI and operations suites. The joint venture is projected to generate approximately $30 million in annual revenue.
RadNet (NASDAQ: RDNT) will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. PT (10:30 a.m. ET). Investors may join by phone or listen to simultaneous and archived webcasts.
Dial-in, international numbers, webcast link, and replay passcode are provided for live participation and later access.
GE HealthCare (Nasdaq: GEHC) expanded its collaboration with DeepHealth (RadNet subsidiary) to commercially extend DeepHealth’s AI-powered Breast Suite internationally and integrate new applications with GE’s Pristina Via mammography systems. The deal adds ProFound Pro, Safeguard Review, and cloud-first workflow tools to scale AI-enabled breast cancer screening and second‑reader workflows.
RadNet (NASDAQ: RDNT) announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 4:30 p.m. ET (1:30 p.m. PT). Live and archived webcasts are available at the provided webcast link.
RadNet (NASDAQ: RDNT) announced that CFO Mark Stolper will present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12, 2026 at 8:00 a.m. ET / 5:00 a.m. PT.
A live webcast and archived replay will be available, and the in-person presentation is scheduled at Loews Miami Beach Hotel.
DeepHealth (NASDAQ: RDNT) unveiled at ECR 2026 a cloud-first, integrated portfolio of native clinical AI solutions across MR, CT, X-ray, mammography and ultrasound, plus the acquisition of Gleamer to expand musculoskeletal and X-ray capabilities.
Key validated results include a 21% breast cancer detection increase across 579,000 women, 92% sensitivity for hippocampal atrophy, deployment across >200 RadNet sites with >94% AI measurement acceptance, and AI Studio aggregating >140 algorithms from 75 partners.
RadNet (NASDAQ: RDNT) will present at the Raymond James 47th Annual Institutional Investors Conference in Orlando on Tuesday, March 3, 2026 at 2:15 p.m. ET. Mark Stolper, EVP and Chief Financial Officer, will deliver the presentation.
A live webcast is available and replay-capable via the company's webcast link, and the conference is at the JW Marriott Grande Lakes, Orlando.
RadNet (NASDAQ: RDNT) reported a quarterly record $547.7M revenue and $87.7M Adjusted EBITDA for Q4 2025, increases of 14.8% and 16.9% year-over-year respectively. Full-year 2025 revenue was $2,040.2M with Adjusted EBITDA of $300.2M.
The company reported strong advanced imaging volume growth, Digital Health momentum (Q4 revenue $27.9M), the Gleamer acquisition, and 2026 guidance calling for double-digit revenue and EBITDA growth across segments.
RadNet (NASDAQ: RDNT) acquired Paris-based Gleamer for up to €230 million, integrating it into DeepHealth to create the world’s largest provider of radiology clinical AI solutions.
Gleamer brings ~130 staff, >700 customer contracts in 44 countries, four FDA-cleared and six CE-marked devices, and an expected $30M ARR in 2026 after >90% ARR CAGR (2022–2025). Deployment across RadNet aims for cost and productivity gains by Q3 2026, with focus on X-ray (≈25% of RadNet volume).